ClinicalTrials.gg
CompletedNCT05112536Updated Mar 12, 2024Results posted

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

A Phase 2 interventional study of Trilaciclib and Cylophosphamide in Triple Negative Breast Cancer and Breast Cancer, sponsored by G1 Therapeutics, Inc.. Completed at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 162 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Enrollment
456th of 605
24 · median 52
Started
2022
with 44 others
Phase 2
191 of 645
45 open now
Registered
441st of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 456th largest by enrollment of the 605 interventional ones that give a count, is one of 45 that started in 2022, is one of 191 in phase 2, and was the 441st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 444 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

162 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast cancer (TNBC).

This study will have four phases: 1) Screening Phase, 2) Trilaciclib Lead-In Phase, 3) Treatment Phase, and 4) Surgery and Follow-Up Phase. After a screening phase of up to 21 day, each participant will receive trilaciclib single-dose monotherapy during the lead-in phase, followed by a tumor biopsy. During the treatment phase, each participant will receive trilaciclib with standard of care chemotherapy. Immunotherapy may be included during the treatment phase, per standard of care. 3-5 weeks following conclusion of the treatment phase, each participant will undergo definitive surgery. A 30-day Safety Follow-up Visit will occur 30 days after the last dose of trilaciclib and an End of Study Visit will occur within 14 days after definitive surgery.

03

Conditions studied

  • Triple Negative Breast Cancer
  • Breast Cancer

Keywords

  • Breast Cancer
  • Triple Negative Breast Cancer
  • CDK4/6 Inhibitor
  • trilaciclib dihydrochloride
  • Cosela
  • Immuno-oncology
  • Solid tumor
  • Chemotherapy-induced myelosuppression
  • Myeloprotective
  • Cyclin-dependent kinase 4/6 inhibitor
  • Neoadjuvant
  • HER2-negative
  • TNBC
  • Breast cancer surgery
  • Trilaciclib
  • Myeloprotection
  • pembrolizumab
  • carboplatin
  • doxorubicin
  • cyclophosphamide
  • Dose-dense anthracycline/cyclophosphamide
  • paclitaxel
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suitability of therapy and patient intends to undergo curative surgery
  • Documented diagnosis of estrogen receptor (ER)-negative and progesterone receptor (PR)-negative tumor
  • Primary tumor ≥ 1.5 cm with any nodal status
  • Provide for the baseline tissue sample
  • performance status of 0 or 1
  • Demonstrates adequate organ function
  • Research tumor biopsies including at least one on-treatment biopsy (and additional biopsy at baseline, if required)
  • Participants of child bearing potential must be willing to use 2 forms of during the study and for 6 months following study treatment

Exclusion criteria

Exclusion Criteria:

  • Prior systemic therapies or radiation for current breast cancer
  • History of invasive ≤3 years prior to signing except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • History of breast cancer including ipsilateral ductal carcinoma in situ (DCIS) treated with radiotherapy at any time
  • Previous exposure to doxorubicin of more than 200 mg/m2 (as lifetime exposure to doxorubicin is not to exceed 450 mg/m2)
  • For patients who will receive pembrolizumab:

    • History of active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, , or drugs). Replacement therapy is not considered a form of systemic treatment
    • Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs
  • History of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Known history of active tuberculosis (Bacillus Tuberculosis)
  • History of severe hepatic impairment
  • Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class II-IV as defined by the [NYHA] functional classification system)
  • Known history of stroke, cerebrovascular accident, severe/unstable angina, myocardial infarction, or coronary angioplasty/stenting/bypass grafting within 6 months prior to enrollment
  • Known serious active infection (e.g., [HIV], or C, tuberculosis).
  • Women who are pregnant or breastfeeding
  • Participation in other studies involving active treatment with drug(s)
  • Prior hematopoietic stem cell or bone marrow transplantation
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Trilaciclib plus chemotherapy

    Trilaciclib lead-in, followed by trilaciclib plus anthracycline/cyclophosphamide, then trilaciclib plus taxane chemotherapy: * Lead-in trilaciclib (240mg/m2) single dose monotherapy * Trilaciclib (240mg/m2) + doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) + pembrolizumab (per Investigator discretion; 400mg) * Trilaciclib (240mg/m2) + paclitaxel (80 mg/m2) + carboplatin (per Investigator discretion; AUC 1.5)

    Drug: Trilaciclib · Drug: Cylophosphamide · Drug: Doxorubicin · Drug: Paclitaxel · Drug: Carboplatin (Investigator discretion) · Biological: Pembrolizumab (Investigator discretion)

Interventions

  • Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.

    Also known as: COSELA®, G1T28

  • Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.

    Also known as: CYTOXAN®

  • Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.

    Also known as: ADRIAMYCIN®

  • Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.

    Also known as: TAXOL®

  • Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).

    Also known as: PARAPLATIN®

  • Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Immune-based Mechanism of Action

    Evaluated 7 days after a single-dose of trilaciclib, measured by the change in CD8+ T cells/regulatory T cells (Treg) ratio in tumor tissue; post-trilaciclib ratio minus pre-trilaciclib ratio. Research shows a correlation between immune cells, (tumor-infiltrating lymphocytes - TILs), and favorable outcomes. Both the presence of effector CD8+ T cells and the ratio of effector CD8+ T cells to immune-suppressive regulatory T cells (Treg) correlate with improved outcome and long-term survival in solid cancers. Therefore, the higher the ratio of CD8+ T cells/Tregs, the better the predicted outcome for a patient. This outcome measure is completed by looking at tumor tissue under a microscope.

    Time frame: Up to 8 days after lead-in trilaciclib dose

Secondary outcomes

  1. Pathologic Complete Response (pCR) Rate

    Rate of pCR using the definition of ypT0/Tis ypN0 (i.e., no invasive residual tumor in breast or nodes; noninvasive breast residuals allowed) as assessed by the local pathologist.

    Time frame: Up to 26 weeks

  2. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Safety/tolerability as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Up to 28 weeks

07

Results

Posted Mar 12, 2024
Limitations and caveats
A limitation of this study was the small number of participants.

Participant flow

Participants were recruited based on physician referral at 7 clinical locations, including academic, community, and hospital network locations. Recruitment occurred between November 2021 and August 2022. The first participant was enrolled on March 3rd, 2022. The last participant was enrolled on August 2nd, 2022.

Participant flow — Overall Study
MilestoneTrilaciclib Plus Chemotherapy
Started24
Completed24
Not completed0

Outcome measures

PrimaryImmune-based Mechanism of Action

Evaluated 7 days after a single-dose of trilaciclib, measured by the change in CD8+ T cells/regulatory T cells (Treg) ratio in tumor tissue; post-trilaciclib ratio minus pre-trilaciclib ratio. Research shows a correlation between immune cells, (tumor-infiltrating lymphocytes - TILs), and favorable outcomes. Both the presence of effector CD8+ T cells and the ratio of effector CD8+ T cells to immune-suppressive regulatory T cells (Treg) correlate with improved outcome and long-term survival in solid cancers. Therefore, the higher the ratio of CD8+ T cells/Tregs, the better the predicted outcome for a patient. This outcome measure is completed by looking at tumor tissue under a microscope.

Time frame:
Up to 8 days after lead-in trilaciclib dose
Reported as:
Median · CD8+/Tregs ratio
Immune-based Mechanism of Action
CD8+/Tregs ratioTrilaciclib Plus Chemotherapy
Immune-based Mechanism of Action0.3 (-0.5 to 2.7)
Statistical analysis
  • Trilaciclib Plus Chemotherapy · Wilcoxon signed-rank test · p = 0.101
SecondaryPathologic Complete Response (pCR) Rate

Rate of pCR using the definition of ypT0/Tis ypN0 (i.e., no invasive residual tumor in breast or nodes; noninvasive breast residuals allowed) as assessed by the local pathologist.

Time frame:
Up to 26 weeks
Reported as:
Count of participants · Participants
Pathologic Complete Response (pCR) Rate
ParticipantsTrilaciclib Plus Chemotherapy
Achieved pCR10
Did not achieve pCR14
SecondaryIncidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

Safety/tolerability as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Time frame:
Up to 28 weeks
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
ParticipantsTrilaciclib Plus Chemotherapy
Adverse Events CTCAE grade >/= 315
Adverse Events CTCAE grade >/= 45
Study drug related adverse event24
Study drug related serious adverse event2
Trilaciclib-related adverse event leading to discontinuation0
Adverse event leading to death0
Trilaciclib adverse events of special interest (AESI)10

Adverse events

Collected over 28 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trilaciclib Plus Chemotherapy0/24 (0%)4/24 (16.7%)24/24 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTrilaciclib Plus Chemotherapy
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/24
Abscess limbInfections and infestations1/24
COVID-19Infections and infestations1/24
Herpes simplex encephalitisInfections and infestations1/24
PneumoniaInfections and infestations1/24
SepsisInfections and infestations1/24
UrosepsisInfections and infestations1/24
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/24
Deep vein thrombosisVascular disorders1/24
Orthostatic hypotensionVascular disorders1/24
Most frequent other events
Showing 10 of 161
Most frequent other events
EventTrilaciclib Plus Chemotherapy
FatigueGeneral disorders21/24
NauseaGastrointestinal disorders20/24
AlopeciaSkin and subcutaneous tissue disorders17/24
HeadacheNervous system disorders12/24
ConstipationGastrointestinal disorders11/24
DiarrhoeaGastrointestinal disorders11/24
Neuropathy peripheralNervous system disorders11/24
StomatitisGastrointestinal disorders10/24
AnaemiaBlood and lymphatic system disorders10/24
NeutropeniaBlood and lymphatic system disorders9/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Trilaciclib Plus Chemotherapy
<=18 years0
Between 18 and 65 years22
>=65 years2
Age, Continuous
Age, Continuous(years)Trilaciclib Plus Chemotherapy
Median57.0 (32 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Trilaciclib Plus Chemotherapy
Female24
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trilaciclib Plus Chemotherapy
Hispanic or Latino3
Not Hispanic or Latino20
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trilaciclib Plus Chemotherapy
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American5
White17
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Trilaciclib Plus Chemotherapy
United States24
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Trilaciclib Plus Chemotherapy
Mean29.88 ± 9.219
Stage at diagnosis
Stage at diagnosis(Participants)Trilaciclib Plus Chemotherapy
Stage I2
Stage II19
Stage III3

5 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • Cancer and Blood Specialty Clinic
    Los Alamitos, California 90720, United States
  • UCLA Department of Medicine - Hematology/Oncology
    Santa Monica, California 90404, United States
  • PIH Health
    Whittier, California 90602, United States
  • Nebraska Hematology-Oncology, P.C.
    Lincoln, Nebraska 68506, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Oct 2022, 7 months.

Results were first posted in Mar 2024, 1 year 4 months after primary completion.

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2021
First posted
Nov 9, 2021
StartActual
Mar 3, 2022
Primary completionActual
Oct 31, 2022
CompletionActual
Mar 13, 2023
Results first posted
Mar 12, 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05112536
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Mar 3, 2022
Primary completion
Oct 31, 2022
Completion
Mar 13, 2023
Results posted
Mar 12, 2024
Last update
Mar 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trilaciclib

Start the discussion